Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sterile Compounders Would Get Tailored Manufacturing Regs If FDA Gets New Authority

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Woodcock says large-scale compounders would not be subject to all current Good Manufacturing Practices, but would be given separate regulations tailored specifically for them, similar to how it handled PET drug requirements.

You may also be interested in...



FDA’s Revised Draft For Compounding Pharmacies Opens Door To Compounding For Office Use

FDA’s revised draft guidance on GMPs for outsourcing pharmacy compounding operations responds to calls to allow the compounding of small quantities of drugs presumably for office use. The IACP applauds the move.

Groups Say GMPs for Compounding Pharmacies are Unworkable

Pharmacy groups and pharmaceutical manufacturers are at odds over the applicability of GMPs to outsourced pharmacy compounding operations. In the meantime, FDA is going full steam ahead and taking an aggressive enforcement approach to compounding pharmacies that violate GMPs, issuing 19 warning letters so far this year.

Compounding Oversight: Could Third-Party Inspection Solve The Problem?

Iowa has contracted with a national pharmacy group to inspect facilities outside its borders. Although the program could serve as a potential model for a nationwide plan, it also could bring several problems.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel